帕利哌酮缓释片治疗精神分裂症的疗效与安全性分析

Paliperidone ER Treatment of Schizophrenia and Safety Analysis

目的探讨帕利哌酮缓释片治疗精神分裂症的疗效和安全性。方法对100名精神分裂症患者进行为期8周的帕利哌酮缓释片系统治疗,在治疗期间定期进行PANSS、TESS、CGI评定以及血常规、生化系列、心电图检查。结果帕利哌酮缓释片治疗前后PANSS、CGI评分差异有统计学意义(P<0.05)。最常见的不良反应是失眠、头痛和静坐不能。结论帕利哌酮缓释片能有效治疗精神分裂症,无严重不良反应,安全性高,服药方便。

Objective To explore the efficacy and tolerability of paliperidone ER on schizophrenia. Methods 100 patients with schizophrenia received 8 weeks, Paliperidone ER treatment. PANSS, CGI, TESS, PSP were assessed and blood routine, biochemistry and ECG were tested periodically. Results All of the subjects had significant difference among baseline PANSS, CGI and PSP after treatment （P 〈 0.05 ）.The common side effects were insomnia, headache and acathisia. Conclusion Pa｜iperidone ER had good efficacy and tolerability on the treatment of schizophrenia.